Metacrine Reports Positive Interim Results with Sustained FXR Agonist in NASH Patients

MET409, a non-bile acid sustained FXR agonist, showed no change in LDL cholesterol, no pruritis and favorable trends in liver fat reduction

SAN DIEGO, May 29, 2019 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, today announced interim results from its Phase 1b clinical study of MET409 in ten patients with nonalcoholic steatohepatitis (NASH).  MET409 dosed orally once-daily at 50 mg resulted in a 20% mean relative reduction in liver fat measured by MRI-PDFF and improved liver function tests after only four weeks of treatment. MET409 was safe and well-tolerated, with no serious adverse events, no changes in LDL cholesterol and no incidence of pruritis. Further details will be presented at an upcoming scientific meeting.

“These initial clinical results with Metacrine’s sustained FXR agonist are highly encouraging,” said Stephen Harrison, MD, Medical Director of Pinnacle Clinical Research, founder of Summit Clinical Research and the principal coordinating investigator of the study. “The lack of LDL cholesterol increase seems to be a differentiating feature from other FXR agonists in development and the early signs of efficacy as judged by rapid liver fat improvement at four weeks is noteworthy.”

These interim results are from an open-label cohort and represent the first of a two-part study evaluating MET409 in NASH patients. The second cohort will evaluate MET409 at higher doses in a double-blind, placebo-controlled, multicenter study design. The study with the second cohort is scheduled to start in June 2019 and will be conducted in partnership with Summit Clinical Research. Initial interim results from this second cohort are expected before the end of 2019.

“Our R&D efforts on FXR have been purposeful to incorporate specific design features to build a best-in-class portfolio,” said Hubert Chen, MD, Chief Medical Officer of Metacrine. “In addition to an improved tolerability profile, the magnitude of liver fat reduction after 4 weeks of treatment with MET409 appears to match or exceed those observed with longer-term dosing of  other FXR agonists.”

NASH is a liver disease caused by excessive fat accumulation in the liver that induces chronic inflammation and ballooning, resulting in progressive fibrosis that can lead to cirrhosis and eventual liver failure requiring liver transplant. There are currently no medications approved for the treatment of NASH. The proportion of liver transplants attributable to NASH has increased significantly in past years and is projected to be the leading cause of liver transplant by the end of 2020.

Metacrine has developed an extensive portfolio of oral FXR agonists that are taken once a day and have sustained activation of the target over 24 hours. MET409 is a representative non-bile acid sustained FXR agonist. The company is developing a “best of breed” FXR agonist from its library of over 2,500 compounds and plans to initiate human clinical studies in early 2020.

About Metacrine

Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Metacrine has purposefully designed a series of compounds to be optimized, next-generation FXR agonists. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities. Privately held Metacrine is headquartered in San Diego, California. For additional information, please visit www.metacrine.com.

Contacts:

Investor Inquiries
Trisha Millican
Chief Financial Officer
858.369.7800
tmillican@metacrine.com

Metacrine to Present at Jefferies 2019 Global Healthcare Conference

SAN DIEGO, May 21, 2019 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, today announced that Ken Song, M.D., President and CEO, will present at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019 at 4:00 p.m. EDT (1:00 p.m. PDT) in New York City.

About Metacrine

Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Metacrine has purposefully designed a series of compounds to be optimized, next-generation FXR agonists. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities. Privately held Metacrine is headquartered in San Diego, California. For additional information, please visit www.metacrine.com.

Contacts:

Investor Inquiries
Trisha Millican
Chief Financial Officer
858.369.7800
tmillican@metacrine.com

Metacrine to Present Relevance of FXR and Specific FXR Drug Profiles for Possible Treatment of Inflammatory Bowel Disease at Digestive Disease Week 2019

SAN DIEGO, May 13, 2019 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, will present data showing efficacy of M480, a potent oral non-bile acid farnesoid X receptor (FXR) agonist, in multiple models of inflammatory bowel disease (IBD). FXR activation increases anti-microbial activity, improves gut barrier function and decreases inflammation which likely explains the benefit observed in IBD models. In a second poster presentation, Metacrine will show that sustained activation of FXR is required to achieve maximal efficacy consistent with what has been shown in preclinical and clinical data in treating patients with nonalcoholic steatophepatitis (NASH). The poster presentations will take place at the Digestive Disease Week 2019 Annual Meeting (DDW 2019) being held in San Diego, California on May 18, 2019.

“Treatment of IBD with an oral and safe FXR drug could be a game changer,” said Ken Song, MD, President and CEO of Metacrine. “Our research now identifies the mechanism by which FXR can modulate IBD. M480 is a predecessor to our lead FXR product candidate(s) which are advancing through various stages of development.”

IBD is a debilitating disease in which most existing therapies are injectable biologics with immunosuppressive side effects. Targeting FXR, a nuclear hormone receptor activated by bile acids, represents a novel approach to treating IBD. FXR is a ligand-activated transcription factor highly expressed in the liver and gastrointestinal tract. Metacrine has developed an extensive portfolio of oral FXR agonists that are taken once a day and have sustained activation of the target over 24 hours.

About Metacrine

Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Metacrine has purposefully designed a series of compounds to be optimized, next-generation FXR agonists. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities. Privately held Metacrine is headquartered in San Diego, California. For additional information, please visit www.metacrine.com.

Contacts:

Investor Inquiries
Trisha Millican
Chief Financial Officer
858.369.7800
tmillican@metacrine.com

Metacrine to Present Phase 1 Results of MET409, an Optimized Next Generation FXR Agonist at The International Liver Congress (EASL) 2019

SAN DIEGO, April 3, 2019 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, will present data showing MET409, a potent, systemic and sustained non-bile acid farnesoid X receptor (FXR) agonist, is safe and well tolerated in a Phase 1 study of healthy subjects. The poster presentation will take place at EASL being held in Vienna, Austria on April 13, 2019.

The Phase 1 study was a 2-part single ascending and multiple ascending design whereby certain subjects received daily doses of MET409 for 14 days at dose levels ranging from 20mg to 150mg. MET409 was found to be safe and well-tolerated with no significant adverse events reported. Importantly, MET409 did not show an increase in LDL cholesterol levels or any pruritus at projected therapeutic doses. In addition, MET409 exhibited a sustained profile based on both drug levels as well as FXR target engagement throughout 24 hours.

“We are highly encouraged by the findings from our Phase 1 study as it shows the sustained target engagement which we view as essential for optimal efficacy and also a differentiated safety profile,” said Ken Song, MD, President and CEO of Metacrine. “Our FXR program has been purposefully designed to generate the best-in-class FXR agonists for NASH and the initial MET409 data is supportive of our approach.”

NASH is a liver disease that exists along a continuum of progressive liver deterioration and is characterized by fatty deposits, inflammation and cellular damage. NASH is expected to be the #1 reason for liver transplant by the year 2020. Targeting FXR, a nuclear hormone receptor, represents a clinically validated and effective approach to treating NASH with the added benefit of improving fibrosis.

MET409 is currently being evaluated in a clinical study in NASH patients with initial data expected this year. In addition, Metacrine continues to advance other FXR agonists beyond MET409 into development.

About Metacrine

Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Metacrine has purposefully designed a series of compounds to be optimized, next-generation FXR agonists . Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities. Privately held Metacrine is headquartered in San Diego, California. For additional information, please visit www.metacrine.com.

Contacts:

Investor Inquiries
Trisha Millican
Chief Financial Officer
858.369.7800
tmillican@metacrine.com

Metacrine to Present Rapid Efficacy of MET409 in a NASH Mouse Model at The Liver Meeting 2018

SAN DIEGO, November 5, 2018 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, will present data showing rapid efficacy of MET409, a potent, systemic and sustained non-bile acid farnesoid X receptor (FXR) agonist in a biopsy confirmed nonalcoholic steatohepatitis (NASH) mouse model. The poster presentation will take place at The Liver Meeting (AASLD 2018) being held in San Francisco, California on November 11, 2018. The abstract can be found on the AASLD 2018 website at https://www.aasld.org/events-professional-development/liver-meeting/abstracts.

NASH is a liver disease that exists along a continuum of progressive liver deterioration and is characterized by fatty deposits, inflammation and cellular damage. NASH is expected to be the #1 reason for liver transplant by the year 2020. Targeting FXR, a nuclear hormone receptor, represents a clinically validated and effective approach to treating NASH with the added benefit of improving fibrosis. FXR is a ligand-activated transcription factor highly expressed in the liver and gastrointestinal tract. The abstract compares the efficacy of MET409, a sustained non-bile acid FXR agonist, in a pre-clinical mouse NASH model to the activity seen with a transient FXR agonist. This pre-clinical disease model is thought to be representative of human NASH.

MET409 demonstrated superior efficacy with 2 weeks of treatment as compared to 8 weeks of treatment with an equally potent transient FXR agonist. MET409 significantly improved fibrosis, while the transient FXR agonist showed no effect on fibrosis. The findings of this study suggest that MET409 is a promising drug candidate for the improvement of liver health by reducing NASH and fibrosis. MET409 is currently being evaluated in a phase 1 clinical study in healthy volunteers to assess safety, pharmacokinetic and pharmacodynamic properties.

About Metacrine

Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. MET409, the lead product candidate, was purposefully designed to be an optimized, next-generation FXR agonist that is initially being developed as a potentially differentiated and best-in-class treatment for nonalcoholic steatohepatitis (NASH). In addition, Metacrine plans to evaluate MET409 as a potential first-in-class treatment for irritable bowel syndrome with diarrhea (IBS-D), and inflammatory bowel diseases (IBD), such as ulcerative
colitis and Crohn’s disease. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities. Privately held Metacrine is headquartered in San Diego, California. For additional information, please visit www.metacrine.com.

Contacts:

Investor Inquiries
Trisha Millican
Chief Financial Officer
858.369.7800
tmillican@metacrine.com

Metacrine Appoints Hubert Chen, M.D. as Chief Medical Officer and Andrew Guggenhime to the Board of Directors

SAN DIEGO, September 6, 2018 – Metacrine, Inc., a biotechnology company developing therapies to benefit patients with liver and gastrointestinal diseases (GI), today announced the appointment of Hubert C. Chen, M.D., as Chief Medical Officer, and Andrew Guggenhime as a director of the company. Dr. Chen most recently served as Chief Medical and Scientific Officer at Pfenex, Inc. Mr. Guggenhime currently serves as Chief Financial Officer of Dermira, Inc.

“We are delighted to have both Hubert and Andrew join Metacrine at this pivotal moment in our company growth,” said Ken Song, M.D., President and Chief Executive Officer of Metacrine. “Hubert’s demonstrated leadership in early and late stage clinical development and regulatory negotiations in several biotechnology companies positions him well to drive progress across our product pipeline. Andrew brings with him a wealth of financial, operational, and managerial experience in the life sciences industry and we look forward to benefiting from his expertise and counsel in the coming years.”

Dr. Chen is a board certified endocrinologist with expertise in both clinical medicine and basic science research. His biotechnology career has spanned early to late stage clinical development in multiple disease areas including hepatitis, fibrosis, and inflammatory disease. Most recently, he served as Pfenex’s Chief Medical and Scientific Officer where he oversaw the development of a biosimilar drug. Previously, he served as Vice President, Clinical Development of Aileron Therapeutics, where he designed and led the company’s first two IND submissions and early clinical development for a novel drug discovery platform. Dr. Chen also held clinical leadership roles at Regulus Therapeutics, Amylin Pharmaceuticals, and Amgen, Inc. Concurrent with his corporate career, Dr. Chen served as Assistant Clinical Professor of Medicine at the University of California, San Francisco. Dr. Chen received his medical residency training at Massachusetts General Hospital, his M.D. from Columbia University and his B.A.S. in political science and biological sciences from Stanford University.

“It is great to be joining the Metacrine team at such an important time in the development of its FXR program,” said Dr. Chen. “I look forward to bringing important therapies to patients with liver and GI diseases.”

As Chief Financial Officer of Dermira, Mr. Guggenhime oversees the finance, corporate communications, corporate development, facilities, information technology, investor relations and legal functions. During his tenure he has helped Demira raise more than $850 million in equity and debt financing. Previously, Andrew was the Chief Financial Officer for CardioDx, Inc., where he also served as a director. He has also served as Chief Financial Officer for Calistoga Pharmaceuticals, Inc. until its acquisition by Gilead, Inc., Facet Biotech Corporation until its acquisition by Abbott Laboratories, PDL BioPharma, Inc., and Neoforma, Inc. Andrew began his career in financial services at Merrill Lynch & Co. and Wells Fargo & Company. He holds a B.A. in international politics and economics from Middlebury College and an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.

“I am pleased to be joining the Metacrine board at an exciting time for the company as it looks to advance several development programs to address underserved liver and GI diseases,” said Andrew Guggenhime. “I look forward to working closely with the Metacrine leadership team and the other directors as they prepare the company for the next phase of the company’s future.”

About Metacrine

Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal, or GI, diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. MET409, the lead product candidate, was purposefully designed to be an optimized, next-generation FXR agonist that is initially being developed as a potentially differentiated and best-in-class treatment for nonalcoholic steatohepatitis (NASH). In addition, Metacrine plans to evaluate MET409 as a potential first-in-class treatment for irritable bowel syndrome with diarrhea (IBS-D), and inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn’s disease. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities. Privately held Metacrine is headquartered in San Diego, California. For additional information, please visit www.metacrine.com.

Contacts:

Investor Inquiries
Trisha Millican
Chief Financial Officer
858.369.7837
tmillican@metacrine.com

Metacrine Completes Dosing of First Cohort in Phase 1 Trial of MET409, a Novel Non-Bile Acid FXR Agonist

San Diego, CA – Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today announced dosing of the first subjects in a Phase 1 randomized, double-blind, placebo-controlled, safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) trial of its lead product candidate MET409. The trial is a single and multiple ascending oral dose administration design that will be conducted in healthy male subjects. The trial is being conducted in the Netherlands.

MET409 is a potent oral non-bile acid small molecule farnesoid X receptor (FXR) agonist. Leveraging its highly experienced internal team in biology and chemistry, Metacrine believes it has identified key factors in regards to FXR engagement that are important for efficacy as well as safety. Developed as a best-in-class FXR agonist, MET409 has the potential to treat patients with non-alcoholic steatohepatitis (NASH), irritable bowel syndrome with diarrhea (IBS-D) and inflammatory bowel disease (IBD).

“The completion of the first dosing cohort with MET409 is a great milestone for the company as we continue clinical development of MET409,” said Ken Song, M.D., President and Chief Executive Officer of Metacrine.

Following the completion of the Phase 1 study in healthy male subjects, Metacrine plans to evaluate MET409 in several parallel Phase 2 clinical trials in patients with NASH, IBS-D and IBD. Metacrine recently completed a $65 million Series C financing to help fund these studies.

About Metacrine

Metacrine is developing best-in-class and first-in-class therapies to benefit patients with liver, gastrointestinal, and metabolic diseases. Metacrine’s lead program for non-alcoholic steatohepatitis (NASH), MET409, focuses on the farnesoid X receptor (FXR) and is based on a novel non-bile acid chemical scaffold. Additional programs are underway in irritable bowel syndrome with diarrhea (IBS-D) and inflammatory bowel disease (IBD) and the company has a research collaboration with Novo Nordisk in type 2 diabetes. Privately held Metacrine is headquartered in San Diego. For additional information, please visit www.metacrine.com.

Contacts:
Investor Inquiries
Westwicke Partners
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com

Metacrine Completes $65 Million Series C Financing

Proceeds will support clinical development of FXR program in NASH and GI diseases

San Diego, CA – Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today announced it has completed a Series C financing which raised $65 million in new funds. The investment was led by Venrock Healthcare Partners and includes new investors Franklin Templeton Investments, Deerfield Management, Arrowmark Partners, Invus, Lilly Asia Ventures, Vivo Capital, and other undisclosed investors. Existing investors Arch Venture Partners, venBio, Polaris Partners, NEA, and Alexandria Venture Investments participated in the financing as well.

Founded in 2015, Metacrine has now raised a total of $125M million in equity financing. Since inception, Metacrine has leveraged its highly experienced internal team in biology, chemistry, and protein engineering to discover and develop novel therapies. The company has judiciously expanded its capabilities to include early development, clinical, and regulatory expertise. With these capabilities, Metacrine has built the infrastructure to advance potential best-in-class novel medicines from discovery through full clinical development.

“The team at Metacrine has repeatedly proven to be scientifically driven, highly productive and very creative,” said Rich Heyman, Ph.D., Chairman of the Board at Metacrine. “We are very pleased to have a leading syndicate of investors to partner with the company to build a lasting enterprise that aims to develop drugs than can materially benefit patients.”

Metacrine’s lead program is focused on the farnesoid X receptor (FXR). FXR represents a promising target to treat non-alcoholic steatohepatitis (NASH), a debilitating condition that is becoming a leading cause for liver transplant and for which no approved therapies exist today. In addition to NASH, Metacrine has identified a potential role for FXR in diarrhea-predominant irritable bowel syndrome (IBS-D) and inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis. Through Metacrine’s discovery efforts and extensive characterization of a broad set of FXR agonists, MET409 has been selected as the lead clinical candidate. MET409 is a non-bile acid FXR agonist and has demonstrated robust preclinical efficacy with a predicted favorable safety profile. While there are a number of FXR agonists in development, Metacrine believes it has identified key factors in regards to FXR engagement that are important for efficacy as well as safety.

“The strong interest from high-quality investors further validates the potential of MET409 for treating liver and gastrointestinal diseases,” said Ken Song, M.D., President and Chief Executive

Officer of Metacrine. “We have purposefully designed an industry leading FXR agonist portfolio with the potential for best-in-class therapy in NASH and first-in-class therapies for IBS-D and IBD.”

Metacrine plans to use proceeds from the Series C financing to advance its clinical development pipeline, including its lead candidate MET409 for the potential treatment of NASH, IBS-D, and inflammatory bowel disease, and to expand its pipeline through continued internal discovery efforts. A Phase 1 clinical study of MET409 is planned to begin later this month.

About Metacrine

Metacrine is developing best-in-class and first-in-class therapies to benefit patients with liver, gastrointestinal, and metabolic diseases. Metacrine’s lead program for non-alcoholic steatohepatitis (NASH), MET409, focuses on the farnesoid X receptor (FXR) and is based on a novel non-bile acid chemical scaffold. Additional programs are underway in irritable bowel syndrome with diarrhea (IBS-D) and inflammatory bowel disease (IBD) and the company has a research collaboration with Novo Nordisk in type 2 diabetes. Privately held Metacrine is headquartered in San Diego.

Contacts:
Investor Inquiries
Westwicke Partners
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com

Metacrine to Present at Jefferies 2018 Global Healthcare Conference

San Diego, CA – Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today announced that Ken Song, M.D., President and CEO, will present at the Jefferies 2018 Global Healthcare Conference on Thursday, June 7, 2018 at 3:30 p.m. EDT (12:30 p.m. PDT) in New York City.

About Metacrine

Metacrine is developing best-in-class and first-in-class therapies to benefit patients with liver, gastrointestinal, and metabolic diseases. Metacrine’s lead program for non-alcoholic steatohepatitis (NASH), MET409, focuses on the farnesoid X receptor (FXR) and is based on a novel non-bile acid chemical scaffold. Additional programs are underway in irritable bowel syndrome with diarrhea (IBS-D) and inflammatory bowel disease (IBD) and the company has a research collaboration with Novo Nordisk in type 2 diabetes. Privately held Metacrine is headquartered in San Diego.

Contacts:
Investor Inquiries
Westwicke Partners
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com

Metacrine to Present Role of FXR in Treating Inflammatory Bowel Disease at Digestive Disease Week 2018

San Diego, CA – Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today presented data showing equivalent efficacy of M480, a potent oral non-bile acid farnesoid X receptor (FXR) agonist for the potential treatment of inflammatory bowel disease (IBD), to anti-IL-12/23, a biologic agent. The oral presentation will take place at the Digestive Disease Week 2018 Annual Meeting (DDW 2018) being held in Washington, D.C. on June 5, 2018 at 4:45pm EDT and presented by Xueqing Liu, PhD, a scientist from Metacrine. The abstract can be found on the DDW 2018 website here

IBD is a debilitating disease in which most existing therapies are injectable biologics with immunosuppressive side effects. Targeting FXR, a nuclear hormone receptor activated by bile acids, represents a novel approach to treating IBD. FXR is a ligand-activated transcription factor highly expressed in the liver and gastrointestinal tract. Metacrine has developed an extensive portfolio of oral FXR agonists that are taken once a day. The abstract compares the efficacy of M480 (a Metacrine developed oral FXR agonist), anti-IL-12/23, and Cyclosporine A (CsA) in the mouse adoptive T-cell transfer model of colitis. This pre-clinical disease model is thought to be more representative of human IBD.

M480 was shown to be efficacious in reducing colitis in the adoptive T-cell transfer model with efficacy superior to CsA and comparable to anti-IL-12/23 treatment. The findings of this study suggest that FXR agonists being developed by Metacrine represent a novel class of oral agents that may offer an alternative treatment for IBD. M480 is a predecessor compound to Metacrine’s lead product candidate MET409 which is entering clinical development this summer.

About Metacrine

Metacrine is developing best-in-class and first-in-class therapies to benefit patients with liver, gastrointestinal, and metabolic diseases. Metacrine’s lead program for non-alcoholic steatohepatitis (NASH), MET409, focuses on the farnesoid X receptor (FXR) and is based on a novel non-bile acid chemical scaffold. Additional programs are underway in irritable bowel syndrome with diarrhea (IBS-D) and inflammatory bowel disease (IBD) and the company has a research collaboration with Novo Nordisk in type 2 diabetes. Privately held Metacrine is headquartered in San Diego.

Contacts:
Investor Inquiries
Westwicke Partners
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com